Where does Ultragenyx Pharmaceutical's cash flow data come from?

Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$574.92M-1.0%	-$569M+6.3%	-$607M+14.2%	-$707.42M-55.8%
Depreciation and amortization	$35M-2.8%	$36M+38.5%	$26M+42.7%	$18.22M+37.6%
Change in accounts receivable	$31M—	——	$23.79M—	——
Change in inventories	——	$11M+57.1%	$7M-27.8%	$9.7M+207%
Other working capital changes	——	——	-$3.1M-1,449%	$230K—
Change in deferred revenue	——	$0+100%	-$1.62M+1.2%	-$1.64M—
Net cash from operating activities	-$466M-12.6%	-$414M+12.8%	-$475M-24.8%	-$380.47M-12.3%
Capital expenditures	$6M-14.3%	$7M-84.1%	$44M-62.1%	$116.12M+58.9%
Purchases of investments	$186M-54.5%	$409M-22.2%	$526M-14.4%	$614.74M-39.3%
Proceeds from maturities/sales of investments	——	$3.15M-93.8%	$51M-39.5%	$84.28M-9.3%
Purchases of intangible assets	——	$13M+333%	$3M—	——
Other investing activities	——	——	$6M+611%	$844K—
Net cash from investing activities	——	——	——	-$291.65M—
Effect of exchange rate changes on cash	——	——	$0—	——
Net increase (decrease) in cash	$252M—	——	$81M+145%	-$178.49M—
Accretion (Amortization) of Discounts and Premiums, Investments	$4M-69.2%	$13M0.0%	$13M—	——
Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost	$153M-3.2%	$158M+17.0%	$135M+3.5%	$130.38M+24.2%
Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities	$24M-48.9%	$47M—	——	$79.85M+147%
Prepaid expenses and other current assets	——	-$12.27M+18.2%	-$15M-295%	-$3.8M—
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties	$61.66M-2.1%	$63M-4.5%	$66M+53.4%	$43.02M+46.2%
Non Cash Royalty Revenue	$112M+10.9%	$101M+46.4%	$69M—	——
Other Noncash Income (Expense)	——	——	-$3.1M-1,449%	$230K—
Payment for (Proceeds from) Other Investing Activity	——	——	$6M+611%	$844K—
Payments to Acquire Intangible Assets	——	$13M+333%	$3M—	——
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$444M+8.3%	$410M-41.1%	$696M+54.4%	$450.71M-37.2%
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	——	——	$0—	——
Free cash flow	-$472M-12.1%	-$421M+18.9%	-$519M-4.5%	-$496.59M-20.6%
Free cash flow	-$472M-12.1%	-$421M+18.9%	-$519M-4.5%	-$496.59M-20.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Ultragenyx Pharmaceutical's cash flow data come from?: Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.